Cargando…

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity

Detalles Bibliográficos
Autores principales:	Auteri, Giuseppe, Bartoletti, Daniela, Di Pietro, Christian, Sutto, Emanuele, Mazzoni, Camilla, Romagnoli, Andrea Davide, Vianelli, Nicola, Lazzarotto, Tiziana, Cavo, Michele, Palandri, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893928/ https://www.ncbi.nlm.nih.gov/pubmed/35303626 http://dx.doi.org/10.1016/j.leukres.2022.106819

Ejemplares similares

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
por: Palandri, F., et al.
Publicado: (2022)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
por: Auteri, Giuseppe, et al.
Publicado: (2021)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

Second versus first wave of COVID-19 in patients with MPN
por: Barbui, Tiziano, et al.
Publicado: (2022)

Long-term follow-up of recovered MPN patients with COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
por: Palandri, Francesca, et al.
Publicado: (2020)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
por: Palandri, Francesca, et al.
Publicado: (2023)

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34(+) Cells
por: Forte, Dorian, et al.
Publicado: (2018)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Response to: Ruxolitinib withdrawal due to the COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
por: Barone, Martina, et al.
Publicado: (2021)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2017)

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
por: Elli, Elena Maria, et al.
Publicado: (2019)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
por: Schmidt, Andreas, et al.
Publicado: (2023)

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
por: Sollazzo, Daria, et al.
Publicado: (2016)

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
por: Barone, Monica, et al.
Publicado: (2021)

Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms
por: Forte, Dorian, et al.
Publicado: (2020)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
por: Li, Hailan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ujkmreg83ufe2vkvkolbalddt